Biotechnology

Experienced Finance and Operations Executive to Join Company on June 12, 2013

Atossa Genetics, Inc. , The Breast Health Company™, will display its ForeCYTE Breast Health Test at the 2013 American Society of Clinical Oncology Annual Meeting in Chicago, from May 31 through June 4, 2013. Atossa's exhibit will be located in ...

NW Bio Exhibit Will Describe DCVax Technology and Clinical Trial Progress at Annual Meeting of Over 25,000 Oncologists

miRagen and Servier announce achievement of first milestone in collaboration to develop microRNA -based drug candidates for the treatment of cardiovascular disease.

A new Tufts CSDD study finds that adoption of adaptive clinical trial designs is increasing and use of simple designs across a portfolio can save sponsor organizations more than $100 million annually.

Receives additional grant support to expand its infectious disease antibody pipeline

Halozyme Therapeutics, Inc. today announced the appointment of David A. Ramsay as Chief Financial Officer. Mr. Ramsay was most recently Vice President, Corporate Development at Halozyme.

Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer

-- First oral proteasome inhibitor investigated in newly diagnosed patients -

SRS, the leader in productivity-enhancing EHR technology and services for high-performance physicians, today announced that East Lansing Orthopedic Association has selected the SRS EHR for its 7 high-volume physicians. East Lansing Orthopedic ...

Pressure BioSciences, Inc. today announced that the Company will host a teleconference to discuss its First Quarter 2013 financial results and to provide a business update. The teleconference information is provided below:

Verastem will present the clinical design for an ongoing study of FAK inhibitor VS-6063 and preclinical data on the dual PI3K/mTOR inhibitor VS-5584 at ASCO, May 31-June 4, 2013.

QUÉBEC CITY, May 23, 2013 /PRNewswire/ - Aeterna Zentaris Inc. today announced that the following posters will be presented on AEZS-108, the Company's lead oncology compound, at the upcoming American Society of Clinical Oncology annual meeting, ...

Jennerex Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today announced that it has completed a ...

Flamel Technologies today announced that it has exercised its right to regain control of two drugs that use its Trigger Lock™ delivery technology that were formerly being developed in partnership with an undisclosed partner. Trigger Lock is ...

Award presented for the poster Contact-Free Under the Mattress Monitoring for Early Recognition of End-of-Life in Med/Surg Units

GUELPH, ON, May 23, 2013 /PRNewswire/ - BIOREM Inc. today announced results for the three month period ended March 31, 2013.  Biorem's complete 2013 first quarter financial statements and MD&A have been filed on SEDAR .

Spectrum Pharmaceuticals to Present Corporate Update at the Deutsche Bank 38th Annual Health Care Conference in Boston on May 30th

The second annual Clinical Research in Georgia Conference will be held on December 4th, 2013, at the Academy of Medicine in the heart of midtown Atlanta. The conference is designed to spotlight innovations that can make clinical trials faster, more ...

Company to Host Conference Call Today at 8:00am ET, 2:00pm CET